As a Keymaker, we know that there isn’t a skeleton key that fits every person. And because of that we work hard to design the support & programing that you, your youth & family needs. That means if ...
As a Keymaker, we know that there isn’t a skeleton key that fits every person. And because of that we work hard to design the support & programing that you, your youth & family needs. That means if ...
Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as adjuvant therapy in ctDNA-positive gastric and esophagogastric junction adenocarcinoma: A protocol for a randomized, ...
Hosted on MSN
Triplet combinations of immunotherapy and targeted treatments as first-line therapy for advanced renal cell carcinoma
KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of pembrolizumab-based immunotherapy and targeted treatments for advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback